Zobrazeno 1 - 10
of 28
pro vyhledávání: '"James H, Zavoral"'
Autor:
Steven R, Smith, Warren A, Prosser, David J, Donahue, Michael E, Morgan, Christen M, Anderson, William R, Shanahan, James H, Zavoral
Publikováno v:
Obesity. 17:494-503
Lorcaserin (APD356) is a potent, selective 5-HT(2C) agonist with ~15-fold and 100-fold selectivity vs. 5-HT(2A) and 5-HT(2B) receptors, respectively. This study evaluated the safety and efficacy of lorcaserin for weight reduction in obese patients du
Autor:
Louis J. Aronne, James W. Anderson, Ken Fujioka, James H. Zavoral, Jonathan Hauptman, James O. Hill, Diane K. Smith, Patrick M. O'Neil
Publikováno v:
The American Journal of Clinical Nutrition. 69:1108-1116
Background: Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment. Objective: This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase in
Publikováno v:
The American Journal of Cardiology. 76:37A-40A
The Fluvastatin Long-Term Extension Trial (FLUENT) was designed to assess the safety and efficacy of fluvastatin over a prolonged period of time. In this way, FLUENT represents a clinical scenario that is closer to office-based chronic treatment of h
Autor:
Antonio M. Gotto, Evan A. Stein, David C. Brown, David W. Bilheimer, James S. Prihoda, Bruce R. Gordon, Peter H. Jones, James H. Zavoral, Sheryl F. Kelsey, Susan F. Leitman, Thomas N. Stern, Robert J. Zwiener, Peter C. Dau, D. Roger Illingworth
Publikováno v:
The American Journal of Cardiology. 70:1010-1016
A subgroup of patients with familial hypercholesterolemia (FH) respond inadequately to standard diet and drug therapy, and are therefore at high risk for the premature development or progression of coronary artery disease. This study evaluated low-de
Autor:
Michael H, Davidson, Michael W, Rooney, Joan, Drucker, H, Eugene Griffin, Sonia, Oosman, Michael, Beckert, James H, Zavoral
Publikováno v:
Clinical therapeutics. 31(12)
Background: Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed. Objective: This study evaluates a new FDC tablet of
Autor:
Joanne L. Slavin, Kim S. Baglien, James H. Zavoral, William C. Duane, William O. Thompson, Johanna W. Lampe
Publikováno v:
The American Journal of Clinical Nutrition. 53:1235-1241
Thirty-four subjects consumed six controlled formula diets for 3 wk each, supplemented with 0 g added fiber, 10 and 30 g dietary fiber as wheat bran (WB), 10 and 30 g dietary fiber as mixed vegetable fiber (VF), and 30 g dietary fiber as sugar-beet f
Autor:
Michael H Davidson, Kevin C Maki, James H Zavoral, Shawn Yu, Clement Popovici, Graham D Price
Publikováno v:
Circulation. 116
Background/Objective: Lapaquistat acetate (LAPA), a novel lipid-lowering agent, inhibits squalene synthase, an enzyme distal to HMG-CoA reductase in the cholesterol biosynthetic pathway. We evaluated the effects of LAPA on LDL-C, other plasma lipid v
Autor:
Scott D. Bergmann, Alba Tres, Francesc Guardiola, Rafael Codony, James H. Zavoral, Paul B. Addis
Publikováno v:
Analytical and bioanalytical chemistry. 389(1)
A gas chromatographic method was successfully applied to determine cholesterol oxidation products (COPs) in human plasma. The linearity, precision, recovery and sensitivity of the method were determined. Oral supplementation with a combination of vit
Autor:
James H. Zavoral
Publikováno v:
Journal of hypertension. 16(12 Pt 2)
To study the efficacy of orlistat, as an adjunct to dietary modification, in weight reduction and modification of cardiovascular risk factors in obese patients after 1 year of treatmentA total of 3132 obese patients (body mass index 28-43 kg/m2) were
Autor:
Therese Heinonen, Donald M. Black, Allan D. Sniderman, James M. McKenney, Frances E. Broyles, Helmut Schrott, Frances Kivel, James H. Zavoral
Publikováno v:
Journal of cardiovascular pharmacology and therapeutics. 1(2)
Background: Atorvastatin, a new HMG-CoA reductase inhibitor in clinical development has demonstrated an acceptable safety profile and marked cholesterol and triglyceride reduction at doses ranging from 10-80 mg/day. Since bile acid sequestering resin